Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Sho ...

Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a ...

The American Gastroenterological Association updated its clinical practice recommendations regarding vaccinations and non-colorectal cancer screenings for people with inflammatory bowel disease. ...

Strategic insight into the Liver Cancer Treatment Market reveals a high-growth opportunity, especially in Asia-Pacific, driven by a rising patient po ...

There's a vaccine for hepatitis B that, according to the CDC, can help to prevent millions of deaths worldwide.

Empathetic and persistent communication is key when it comes to talking to parents who are reluctant to vaccinate their child ...

The Global Cancer Vaccines Market is experiencing a significant growth phase, with its valuation rising from $4,188 million in 2019 to an expected $7,303 million by 2027. This rep ...

The role of insects in drug discovery is expanding, with biopharmaceuticals derived from insect cells offering sustainable ...

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University Atlanta, Atlanta, Georgia 30322, United States ...